Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations
about
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypesNatural host genetic resistance to lentiviral CNS disease: a neuroprotective MHC class I allele in SIV-infected macaquesRedefining the viral reservoirs that prevent HIV-1 eradicationStructural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphismsMutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infectionsImmunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trialCD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatoryA whole-genome association study of major determinants for host control of HIV-1Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1HLA alleles associated with slow progression to AIDS truly prefer to present HIV-1 p24.Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.The evolutionary selective advantage of HIV-1 escape variants and the contribution of escape to the HLA-associated risk of AIDS progression.HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 allelesElite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsBreadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesHighly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.Unexpected diversity of cellular immune responses against Nef and Vif in HIV-1-infected patients who spontaneously control viral replicationQuantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes.Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers.A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic ControllersElite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART.Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.Association of single nucleotide polymorphisms in the lens epithelium-derived growth factor (LEDGF/p75) with HIV-1 infection outcomes in Brazilian HIV-1+ individualsImpaired replication capacity of acute/early viruses in persons who become HIV controllers.Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllersGenetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.Molecular characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, and impact of T-cell epitope mutations on HLA recognition (ANRS 12159).Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells.Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.HIV-1 continues to replicate and evolve in patients with natural control of HIV infectionMacaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus.Control of viral replication after cessation of HAARTCD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressorRapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretro
P2860
Q24612992-4B982298-CED0-484E-BCCE-27C9F28E4482Q24647731-330ECEF1-1390-4623-8582-6D1E535BB297Q26827255-D8514D49-4D2C-49D9-8EF7-EDD9FB003294Q27675160-D4A9572F-3B55-4408-9173-E0964D14CDDEQ28086907-1D10A643-549F-491A-8F13-50A51894A9A1Q28469122-1C8F3E7A-BC79-43F6-9F3D-14D2ABF1BA24Q28477861-523BDF3F-B27B-4B45-894E-6A3E7A9D9F77Q29614891-3C951482-C36E-48ED-A68E-410D70034618Q33290217-4F9AB70D-19A1-4998-A48A-32886070A5D9Q33299493-920FC0DC-05C6-458B-A254-3976C63BAFE0Q33325923-B48829BE-628A-48C9-8FAB-D7C9AF782020Q33378477-55508F6E-16D1-484B-A58B-39556C1DB591Q33382373-66E49216-1F30-4FE5-AB51-21AD5178316BQ33429049-FF127CF1-BC90-43B7-BA4D-553DEA34EE58Q33614495-0EEDB8A9-027D-4884-9841-96870C04BF1DQ33630471-0080771A-E52D-4DA1-8E24-CBB2887CE593Q33631183-EEFF3682-D762-44AB-A924-0BD5C4B10C6AQ33747537-16D2BC8B-D024-4B88-B186-146A01BB2392Q33805995-D5E9A9C1-3FBD-4452-ABA6-FED379A7162AQ33815728-9D064C49-2C04-4736-B65E-C63E78EAECB2Q33828507-2CC705D2-864A-4F54-97B9-0458DFFC7B5AQ33839450-E870C6B4-910A-4494-859E-71FE94109215Q33839468-D147BDDF-D5F1-4603-A5CF-1B7D1D0D8590Q33928605-F8FFFA4E-C173-4494-B619-89DC7EA633A0Q33963989-F7D44B6F-30D4-4948-96F4-4D057EF23D9FQ33966626-7EBDFDC3-FF3C-4A20-88E6-D4BE992014CDQ33982102-156178C2-0588-4438-857D-DDAF8B16C3B4Q34009945-A6F9EF56-43E7-4254-BDD7-2920DAA36AE4Q34057338-587B788C-C4F2-4AED-817F-EDDCA7FFDC8BQ34062308-72C7EF0F-0F7D-4F1B-9C14-756C98D7FAECQ34206267-0C4D48FB-1B6F-4C93-9B25-F754AF9BF667Q34292622-0CE48B51-C317-4F94-B426-04A71BEA701AQ34416428-6B4618F5-0228-456C-9E19-9AE947364C16Q34457852-05053029-5254-46D2-A61D-606A93406E79Q34615847-62D5D0EC-EA33-4283-8D5D-95475803AC4BQ34677320-97E344EC-462A-4AEF-9BA9-9917B5BE5820Q34780395-BC5C88B3-59F0-4327-8145-C7A986FF85FEQ34819446-141FECFD-548F-481A-A3C6-D62C4475A5FEQ34874985-19373052-5999-457D-9A4B-C544167D7C4AQ34992440-8A911471-AD2A-4FCD-AB00-448257325FA8
P2860
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Maintenance of viral suppressi ...... s despite CTL escape mutations
@ast
Maintenance of viral suppressi ...... s despite CTL escape mutations
@en
type
label
Maintenance of viral suppressi ...... s despite CTL escape mutations
@ast
Maintenance of viral suppressi ...... s despite CTL escape mutations
@en
prefLabel
Maintenance of viral suppressi ...... s despite CTL escape mutations
@ast
Maintenance of viral suppressi ...... s despite CTL escape mutations
@en
P2093
P2860
P356
P1476
Maintenance of viral suppressi ...... s despite CTL escape mutations
@en
P2093
Joel N Blankson
Justin R Bailey
Thomas M Williams
P2860
P304
P356
10.1084/JEM.20052319
P407
P577
2006-05-08T00:00:00Z